Table 1.
Baseline patient characteristics
| Characteristics | Sorafenib alone (n = 41) |
Sorafenib + HAIC (cisplatin) (n = 65) |
||
|---|---|---|---|---|
| Number of patients | % | Number of patients | % | |
| Age, years | ||||
| Median | 64 | 66 | ||
| Range | 42–78 | 25–79 | ||
| Sex | ||||
| Male | 32 | 78.1 | 56 | 86.2 |
| Female | 9 | 22.0 | 9 | 13.8 |
| ECOG performance status | ||||
| 0 | 33 | 80.5 | 50 | 76.9 |
| 1 | 8 | 19.5 | 15 | 23.1 |
| Etiology | ||||
| Hepatitis B | 9 | 22.0 | 22 | 33.8 |
| Hepatitis C | 20 | 48.8 | 18 | 27.7 |
| Child-Pugh score | ||||
| 5 | 27 | 65.9 | 38 | 58.5 |
| 6 | 12 | 29.3 | 19 | 29.2 |
| 7 | 2 | 4.9 | 8 | 12.3 |
| Ascites | 4 | 9.8 | 10 | 15.4 |
| Previous therapy | 21 | 51.2 | 33 | 50.8 |
| Resection | 6 | 17 | ||
| PEI/RFA | 7 | 8 | ||
| TACE | 14 | 23 | ||
| Radiation | 1 | 1 | ||
| Other | 2 | 1 | ||
| BCLC stage | ||||
| B | 16 | 39.0 | 19 | 29.2 |
| C | 25 | 61.0 | 46 | 70.8 |
| Portal vein tumor thrombosis | 17 | 41.5 | 40 | 61.5 |
| Vp1 | 0 | 4 | 10.0 | |
| Vp2 | 4 | 23.5 | 9 | 22.5 |
| Vp3 | 7 | 41.4 | 14 | 35.0 |
| Vp4 | 6 | 35.3 | 13 | 32.5 |
| Extrahepatic spread | 13 | 31.7 | 19 | 29.2 |
| Lung | 6 | 8 | ||
| Bone | 3 | 1 | ||
| Lymph node | 6 | 10 | ||
| Adrenal | 1 | 1 | ||
| Other | 2 | 4 | ||
| Number of tumors | ||||
| 1 | 4 | 9.8 | 8 | 12.3 |
| 2 | 3 | 7.3 | 5 | 7.7 |
| 3 | 1 | 2.4 | 1 | 1.5 |
| 4 | 3 | 7.3 | 5 | 7.7 |
| ≥5 | 30 | 73.2 | 46 | 70.8 |
| Maximum tumor size, cm | ||||
| Median | 5.2 | 5.1 | ||
| Range | 1.1–17.5 | 1.0–20.0 | ||
| Serum α-fetoprotein, ng/ml | ||||
| Median | 188 | 223.5 | ||
| Range | 2–749 412 | 1.2–394 944 | ||
| PIVKA II, mAU/ml | ||||
| Median | 1790 | 1772 | ||
| Range | 9–1 410,000 | 10–261 920 | ||
ECOG, Eastern Cooperative Oncology Group; PEI/RFA, percutaneous ethanol injection/radiofrequency ablation; TACE, transarterial chemoembolization; BCLC, Barcelona Clinic Liver Cancer Group; Vp1, tumor thrombosis distal to the second branches of the portal vein; Vp2, tumor thrombosis in the second branches of the portal vein; Vp3, tumor thrombosis in the first branches of the portal vein; Vp4, tumor thrombosis in the main trunk of the portal vein or the opposite side branch of the portal vein; PIVKA II, protein induced by vitamin K absence or antagonist-II.